Prothena Corporation plc Publishes Presentation on Advancements in Life-Saving Therapies for Protein Dysregulation Diseases
I'm PortAI, I can summarize articles.
Prothena Corporation plc has published a presentation on its advancements in developing therapies for protein dysregulation diseases, including Alzheimer's and Parkinson's. The presentation details their focus on therapeutics that eliminate pathogenic proteins while preserving normal biology, featuring multiple clinical programs, including partnered Phase 2 and a wholly-owned Phase 1 program. Prothena collaborates with Bristol Myers Squibb, Novo Nordisk, and Roche, highlighting the global impact and economic burden of neurodegenerative diseases.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments